Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

LUCIAN M MANU

Allopathic & Osteopathic Physicians Psychiatry & Neurology Psychiatry

NPI
1316934300
CMS profile
1083171
Location
STONY BROOK, NY

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2022 · Entire year

$8,825.02

14 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2022 · entire year · sorted by reported total

By paying entity

PY2022 · entire year · sorted by reported total

Paying entityAmountRecords
Janssen Pharmaceuticals, Inc $8,710.41 13
LivaNova USA, Inc. $114.61 1

Page 1 of 1; records 1–14 of 14 matching records. This page contains 14 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

LUCIAN M MANU

NPI 1316934300 · CMS profile ID 1083171

Allopathic & Osteopathic Physicians / Psychiatry & Neurology / Psychiatry

STONY BROOK, NY

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–14 of 14 matching records. This page contains 14 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1316934300?year=2022&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
LUCIAN M MANU, NPI 1316934300, CMS profile ID 1083171. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–14 of 14 matching records. This page contains 14 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1316934300?year=2022&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
APA 7
IndustryPayments. (2026). LUCIAN M MANU, NPI 1316934300, CMS profile ID 1083171. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–14 of 14 matching records. This page contains 14 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1316934300?year=2022&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
Bluebook
LUCIAN M MANU, NPI 1316934300, CMS profile ID 1083171, IndustryPayments, General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–14 of 14 matching records. This page contains 14 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c. https://industrypayments.org/provider/npi-1316934300?year=2022&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2022

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2022 · Physicians and non-physician practitioners · CMS publication 2026-06-30

14 matching records · $8,825.02 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 14 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–14 of 14.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
LivaNova USA, Inc. $114.6108/30/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 942175803 CMS
Janssen Pharmaceuticals, Inc $3,500.0007/06/2022 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 886769817 CMS
Janssen Pharmaceuticals, Inc $30.8804/10/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 886769841 CMS
Janssen Pharmaceuticals, Inc $13.2404/10/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 886769845 CMS
Janssen Pharmaceuticals, Inc $44.1204/10/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 886769849 CMS
Janssen Pharmaceuticals, Inc $13.2404/10/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 886769853 CMS
Janssen Pharmaceuticals, Inc $208.2904/09/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 886769821 CMS
Janssen Pharmaceuticals, Inc $42.1104/09/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 886769825 CMS
Janssen Pharmaceuticals, Inc $10.5204/09/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 886769829 CMS
Janssen Pharmaceuticals, Inc $8.5504/09/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 886769833 CMS
Janssen Pharmaceuticals, Inc $105.0904/09/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 886769837 CMS
Janssen Pharmaceuticals, Inc $2,340.0003/28/2022 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 886769813 CMS
Janssen Pharmaceuticals, Inc $54.3703/09/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 886769857 CMS
Janssen Pharmaceuticals, Inc $2,340.0001/11/2022 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 886769809 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $64,992.38 96
PY2020 $10,915.59 11
PY2021 $27,775.08 29
PY2022 $8,825.02 14
PY2023 $11,122.83 20
PY2024 $14,443.61 24
PY2025 $39,719.40 30

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $119,547.08 149
PY2024 Principal investigator $72,614.39 43
PY2023 Principal investigator $150,498.78 26
PY2022 Principal investigator $288,796.99 36
PY2021 Principal investigator $13,015.67 9
PY2020 Principal investigator $10,500.00 3
PY2019 Principal investigator $19,364.44 6

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2022

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

36 records in PY2022

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Janssen Research & Development, LLC $13,885.00 12/19/2022 Non-covered Recipient Entity
THE RESEARCH FOUNDATION OF STATE UN IVERSITY OF NEW YORK
A Study of Esketamine Nasal Spray Administered as Monotherapy in Adult Participants With Treatment resistant Depression No dispute reported 06/30/2026 885245729
Principal investigator 1 LivaNova USA, Inc. $17,181.25 12/01/2022 Non-covered Recipient Entity
Stony Brook University Hospital-Stony Brook Psychiatric Associates
A Prospective, Multi-center, Randomized Controlled Blinded Trial Demonstrating the Safety and Effectiveness of VNS Therapy System as Adjunctive Therapy Versus a No Stimulation Control in Subjects With Treatment-Resistant Depression (RECOVER) No dispute reported 06/30/2026 942168853
Principal investigator 1 Janssen Research & Development, LLC $687.50 11/28/2022 Non-covered Recipient Entity
THE RESEARCH FOUNDATION OF STATE UN IVERSITY OF NEW YORK
A Study of Esketamine Nasal Spray Administered as Monotherapy in Adult Participants With Treatment resistant Depression No dispute reported 06/30/2026 885245725
Principal investigator 1 LivaNova USA, Inc. $1,400.00 11/22/2022 Non-covered Recipient Entity
Stony Brook University Hospital-Stony Brook Psychiatric Associates
A Prospective, Multi-center, Randomized Controlled Blinded Trial Demonstrating the Safety and Effectiveness of VNS Therapy System as Adjunctive Therapy Versus a No Stimulation Control in Subjects With Treatment-Resistant Depression (RECOVER) No dispute reported 06/30/2026 942168877
Principal investigator 1 Janssen Research & Development, LLC $1,700.00 11/07/2022 Non-covered Recipient Entity
THE RESEARCH FOUNDATION OF STATE UN IVERSITY OF NEW YORK
A Study of Esketamine Nasal Spray Administered as Monotherapy in Adult Participants With Treatment resistant Depression No dispute reported 06/30/2026 885245723
Principal investigator 1 LivaNova USA, Inc. $6,500.00 11/02/2022 Non-covered Recipient Entity
Stony Brook University Hospital-Stony Brook Psychiatric Associates
A Prospective, Multi-center, Randomized Controlled Blinded Trial Demonstrating the Safety and Effectiveness of VNS Therapy System as Adjunctive Therapy Versus a No Stimulation Control in Subjects With Treatment-Resistant Depression (RECOVER) No dispute reported 06/30/2026 942168859
Principal investigator 1 Janssen Research & Development, LLC $1,350.00 10/31/2022 Non-covered Recipient Entity
THE RESEARCH FOUNDATION OF STATE UN IVERSITY OF NEW YORK
A Study of Esketamine Nasal Spray Administered as Monotherapy in Adult Participants With Treatment resistant Depression No dispute reported 06/30/2026 885245717
Principal investigator 1 Janssen Research & Development, LLC $3,350.00 10/31/2022 Non-covered Recipient Entity
THE RESEARCH FOUNDATION OF STATE UN IVERSITY OF NEW YORK
A Study of Esketamine Nasal Spray Administered as Monotherapy in Adult Participants With Treatment resistant Depression No dispute reported 06/30/2026 885245719
Principal investigator 1 Janssen Research & Development, LLC $350.00 10/31/2022 Non-covered Recipient Entity
THE RESEARCH FOUNDATION OF STATE UN IVERSITY OF NEW YORK
A Study of Esketamine Nasal Spray Administered as Monotherapy in Adult Participants With Treatment resistant Depression No dispute reported 06/30/2026 885245721
Principal investigator 1 LivaNova USA, Inc. $1,275.00 10/18/2022 Non-covered Recipient Entity
Stony Brook University Hospital-Stony Brook Psychiatric Associates
A Prospective, Multi-center, Randomized Controlled Blinded Trial Demonstrating the Safety and Effectiveness of VNS Therapy System as Adjunctive Therapy Versus a No Stimulation Control in Subjects With Treatment-Resistant Depression (RECOVER) No dispute reported 06/30/2026 942168871
Principal investigator 1 LivaNova USA, Inc. $3,950.00 10/12/2022 Non-covered Recipient Entity
Stony Brook University Hospital-Stony Brook Psychiatric Associates
A Prospective, Multi-center, Randomized Controlled Blinded Trial Demonstrating the Safety and Effectiveness of VNS Therapy System as Adjunctive Therapy Versus a No Stimulation Control in Subjects With Treatment-Resistant Depression (RECOVER) No dispute reported 06/30/2026 942168865
Principal investigator 1 LivaNova USA, Inc. $1,400.00 09/28/2022 Non-covered Recipient Entity
TRINITY MEDICAL OF WNYPC
A Prospective, Multi-center, Randomized Controlled Blinded Trial Demonstrating the Safety and Effectiveness of VNS Therapy System as Adjunctive Therapy Versus a No Stimulation Control in Subjects With Treatment-Resistant Depression No dispute reported 06/30/2026 942171095
Principal investigator 1 LivaNova USA, Inc. $1,400.00 09/20/2022 Non-covered Recipient Entity
Stony Brook University Hospital-Stony Brook Psychiatric Associates
A Prospective, Multi-center, Randomized Controlled Blinded Trial Demonstrating the Safety and Effectiveness of VNS Therapy System as Adjunctive Therapy Versus a No Stimulation Control in Subjects With Treatment-Resistant Depression No dispute reported 06/30/2026 942168731
Principal investigator 1 LivaNova USA, Inc. $8,300.00 09/09/2022 Non-covered Recipient Entity
Stony Brook University Hospital-Stony Brook Psychiatric Associates
A Prospective, Multi-center, Randomized Controlled Blinded Trial Demonstrating the Safety and Effectiveness of VNS Therapy System as Adjunctive Therapy Versus a No Stimulation Control in Subjects With Treatment-Resistant Depression No dispute reported 06/30/2026 942168725
Principal investigator 1 LivaNova USA, Inc. $44,000.00 09/08/2022 Non-covered Recipient Entity
Stony Brook University
RECOVER: A Prospective, Multi-cEnter, Randomized Controlled Blinded Trial DemOnstrating the Safety and Effectiveness of VNS Therapy System as AdjunctivE Therapy Versus a No-Stimulation Control in Subjects with Treatment-Resistant Depression No dispute reported 06/30/2026 965169017
Principal investigator 1 LivaNova USA, Inc. $7,363.76 09/07/2022 Non-covered Recipient Entity
Stony Brook University Hospital-Stony Brook Psychiatric Associates
A Prospective, Multi-center, Randomized Controlled Blinded Trial Demonstrating the Safety and Effectiveness of VNS Therapy System as Adjunctive Therapy Versus a No Stimulation Control in Subjects With Treatment-Resistant Depression No dispute reported 06/30/2026 942168717
Principal investigator 1 Janssen Research & Development, LLC $3,350.00 08/08/2022 Non-covered Recipient Entity
THE RESEARCH FOUNDATION OF STATE UN IVERSITY OF NEW YORK
A Study of Esketamine Nasal Spray Administered as Monotherapy in Adult Participants With Treatment resistant Depression No dispute reported 06/30/2026 885245713
Principal investigator 1 Janssen Research & Development, LLC $3,350.00 08/08/2022 Non-covered Recipient Entity
THE RESEARCH FOUNDATION OF STATE UN IVERSITY OF NEW YORK
A Study of Esketamine Nasal Spray Administered as Monotherapy in Adult Participants With Treatment resistant Depression No dispute reported 06/30/2026 885245715
Principal investigator 1 LivaNova USA, Inc. $300.00 08/04/2022 Non-covered Recipient Entity
Stony Brook University Hospital-Stony Brook Psychiatric Associates
A Prospective, Multi-center, Randomized Controlled Blinded Trial Demonstrating the Safety and Effectiveness of VNS Therapy System as Adjunctive Therapy Versus a No Stimulation Control in Subjects With Treatment-Resistant Depression No dispute reported 06/30/2026 942168749
Principal investigator 1 LivaNova USA, Inc. $750.00 08/04/2022 Non-covered Recipient Entity
Washington University
A Prospective, Multi-center, Randomized Controlled Blinded Trial Demonstrating the Safety and Effectiveness of VNS Therapy System as Adjunctive Therapy Versus a No Stimulation Control in Subjects With Treatment-Resistant Depression No dispute reported 06/30/2026 942170593
Principal investigator 1 LivaNova USA, Inc. $12,919.42 07/27/2022 Non-covered Recipient Entity
Stony Brook University Hospital-Stony Brook Psychiatric Associates
A Prospective, Multi-center, Randomized Controlled Blinded Trial Demonstrating the Safety and Effectiveness of VNS Therapy System as Adjunctive Therapy Versus a No Stimulation Control in Subjects With Treatment-Resistant Depression No dispute reported 06/30/2026 942168737
Principal investigator 1 LivaNova USA, Inc. $5,314.15 07/27/2022 Non-covered Recipient Entity
Stony Brook University Hospital-Stony Brook Psychiatric Associates
A Prospective, Multi-center, Randomized Controlled Blinded Trial Demonstrating the Safety and Effectiveness of VNS Therapy System as Adjunctive Therapy Versus a No Stimulation Control in Subjects With Treatment-Resistant Depression No dispute reported 06/30/2026 942168755
Principal investigator 1 LivaNova USA, Inc. $8,074.38 06/30/2022 Non-covered Recipient Entity
Stony Brook University Hospital-Stony Brook Psychiatric Associates
The RECOVERsUb-study, Which Leverages quaNtitative and Credible Research tOols From Verily, Will providE Assessment measuRes for Depressive Episodes No dispute reported 06/30/2026 942168617
Principal investigator 1 LivaNova USA, Inc. $1,275.00 06/23/2022 Non-covered Recipient Entity
Stony Brook University Hospital-Stony Brook Psychiatric Associates
The RECOVERsUb-study, Which Leverages quaNtitative and Credible Research tOols From Verily, Will providE Assessment measuRes for Depressive Episodes No dispute reported 06/30/2026 942168603
Principal investigator 1 LivaNova USA, Inc. $15,207.51 06/09/2022 Non-covered Recipient Entity
Stony Brook University Hospital-Stony Brook Psychiatric Associates
The RECOVERsUb-study, Which Leverages quaNtitative and Credible Research tOols From Verily, Will providE Assessment measuRes for Depressive Episodes No dispute reported 06/30/2026 942168591
Principal investigator 1 LivaNova USA, Inc. $3,931.25 05/25/2022 Non-covered Recipient Entity
Stony Brook University Hospital-Stony Brook Psychiatric Associates
The RECOVERsUb-study, Which Leverages quaNtitative and Credible Research tOols From Verily, Will providE Assessment measuRes for Depressive Episodes No dispute reported 06/30/2026 942168609
Principal investigator 1 LivaNova USA, Inc. $18,265.66 05/12/2022 Non-covered Recipient Entity
Stony Brook University Hospital-Stony Brook Psychiatric Associates
The RECOVERsUb-study, Which Leverages quaNtitative and Credible Research tOols From Verily, Will providE Assessment measuRes for Depressive Episodes No dispute reported 06/30/2026 942168597
Principal investigator 1 LivaNova USA, Inc. $14,368.75 05/05/2022 Non-covered Recipient Entity
Stony Brook University Hospital-Stony Brook Psychiatric Associates
The RECOVERsUb-study, Which Leverages quaNtitative and Credible Research tOols From Verily, Will providE Assessment measuRes for Depressive Episodes No dispute reported 06/30/2026 942168584
Principal investigator 1 LivaNova USA, Inc. $44,000.00 05/03/2022 Non-covered Recipient Entity
Stony Brook University
RECOVER: A Prospective, Multi-cEnter, Randomized Controlled Blinded Trial DemOnstrating the Safety and Effectiveness of VNS Therapy System as AdjunctivE Therapy Versus a No-Stimulation Control in Subjects with Treatment-Resistant Depression No dispute reported 06/30/2026 965169015
Principal investigator 1 LivaNova USA, Inc. $781.25 03/31/2022 Non-covered Recipient Entity
Stony Brook University Hospital-Stony Brook Psychiatric Associates
A Prospective, Multi-center, Randomized Controlled Blinded Trial Demonstrating the Safety and Effectiveness of VNS Therapy System as Adjunctive Therapy Versus a No Stimulation Control in Subjects With Treatment-Resistant Depression No dispute reported 06/30/2026 942168501
Principal investigator 1 LivaNova USA, Inc. $4,447.92 03/17/2022 Non-covered Recipient Entity
Stony Brook University Hospital-Stony Brook Psychiatric Associates
A Prospective, Multi-center, Randomized Controlled Blinded Trial Demonstrating the Safety and Effectiveness of VNS Therapy System as Adjunctive Therapy Versus a No Stimulation Control in Subjects With Treatment-Resistant Depression No dispute reported 06/30/2026 942168495
Principal investigator 1 LivaNova USA, Inc. $2,400.00 03/10/2022 Non-covered Recipient Entity
Stony Brook University Hospital-Stony Brook Psychiatric Associates
A Prospective, Multi-center, Randomized Controlled Blinded Trial Demonstrating the Safety and Effectiveness of VNS Therapy System as Adjunctive Therapy Versus a No Stimulation Control in Subjects With Treatment-Resistant Depression No dispute reported 06/30/2026 942168477
Principal investigator 1 LivaNova USA, Inc. $6,996.89 02/17/2022 Non-covered Recipient Entity
Stony Brook University Hospital-Stony Brook Psychiatric Associates
A Prospective, Multi-center, Randomized Controlled Blinded Trial Demonstrating the Safety and Effectiveness of VNS Therapy System as Adjunctive Therapy Versus a No Stimulation Control in Subjects With Treatment-Resistant Depression No dispute reported 06/30/2026 942168489
Principal investigator 1 Janssen Research & Development, LLC $16,530.00 01/14/2022 Non-covered Recipient Entity
THE RESEARCH FOUNDATION OF STATE UN IVERSITY OF NEW YORK
A Study of Esketamine Nasal Spray Administered as Monotherapy in Adult Participants With Treatment resistant Depression No dispute reported 06/30/2026 885245707
Principal investigator 1 Janssen Research & Development, LLC $11,885.00 01/14/2022 Non-covered Recipient Entity
THE RESEARCH FOUNDATION OF STATE UN IVERSITY OF NEW YORK
A Study of Esketamine Nasal Spray Administered as Monotherapy in Adult Participants With Treatment resistant Depression No dispute reported 06/30/2026 885245709
Principal investigator 1 LivaNova USA, Inc. $557.30 01/12/2022 Non-covered Recipient Entity
Stony Brook University Hospital-Stony Brook Psychiatric Associates
A Prospective, Multi-center, Randomized Controlled Blinded Trial Demonstrating the Safety and Effectiveness of VNS Therapy System as Adjunctive Therapy Versus a No Stimulation Control in Subjects With Treatment-Resistant Depression No dispute reported 06/30/2026 942168483